Siemens is planning to spin out its Healthineers business in an IPO slated for the first half of next year, the German conglomerate has confirmed. The move will give the health care business "the required currency and entrepreneurial flexibility" to grow in a fundamentally attractive market, it said. The announcement was made in conjunction with the group's reporting of its third quarter results for fiscal 2017, in which solid diagnostics imaging sales helped to boost the top line for Healthineers.
Following months of unconfirmed rumors and reports from sources close to the matter, Siemens AG has now confirmed it is planning to float its health care business, Healthineers, as an independent publicly-listed company and is targeting to complete the IPO in the first half of 2018, depending on market conditions.
The disclosure came during an Aug 3 investor conference call held by the German conglomerate to discuss its third fiscal...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
